Sign In

Jeb Keiper

Chief Executive Officer at Nimbus Therapeutics

Jeb Keiper is a highly accomplished professional serving as the Chief Executive Officer of Nimbus Therapeutics, a renowned biotechnology company specializing in discovering groundbreaking medicines targeting previously inaccessible drug targets.

With an impressive career spanning prominent roles across leading organizations, Jeb Keiper has been instrumental in driving strategic growth and financial success. He initially joined Nimbus in 2014 as the Chief Business Officer and later assumed the position of Chief Financial Officer in 2017.

During his tenure at Nimbus, Jeb played a pivotal role in securing over $775 million in partnerships and financing, notable among them being the sale of Nimbus' clinical NASH program to Gilead for $400 million upfront and forging a strategic immunology alliance with Celgene.

Apart from his contributions at Nimbus, Jeb Keiper has a rich professional background, having served as the VP of Business Development at GSK Oncology and held various leadership roles at GlaxoSmithKline where he led the oncology segment of the GSK-Novartis business swap worth $16 billion.

Jeb's journey began at Pfizer R&D as a bench chemist and further expanded through consulting at McKinsey, working in business development at TransForm Pharmaceuticals, and serving in different BD leadership capacities at GSK.

Noteworthy is Jeb's educational background, holding four degrees from MIT, including an MBA from the Sloan School of Management, reflecting his strong academic foundation and expertise in chemistry and chemical engineering.

Besides his roles at Nimbus and GSK, Jeb Keiper has been recognized as an independent director on the board of Cardurion Pharmaceuticals, a clinical-stage company focused on cardiovascular diseases, showcasing his versatility and influence in the biopharmaceutical industry.

Currently, as the CEO of Nimbus Therapeutics and a member of the board at ROME Therapeutics, Jeb Keiper continues to drive innovation, strategic partnerships, and business growth in the field of biotechnology.

Highlights

Sep 11 · linkedin

Terrific top line results in psoriatic arthritis patients for Takeda’s newly-acquired-from-Nimbus Therapeutics super selective allosteric TYK2 inhibitor TAK-279 née NDI-034858. Will need to wait just a bit for full data. So proud of everyone involved in this study.

Apr 25 · linkedin

I'm raising awareness and fundraising for Special Olympics Massachusetts through the annual Bio-Ball tournament! This is a great event the life sciences community puts on, and you can help simply by liking or re-sharing this post! I'll donate $1 to Special Olympics for each like this post gets, and $5 for each re-post, between now and the end of May 2023. If you are even more inspired to help, you can support my efforts and donate directly or via my fundraising page below, or to anyone on Team Nimbus Therapeutics or any of the other great biotech companies participating. Thank you! https://lnkd.in/eT8Krec4

Jeb Keiper
Add to my network

Location

Cambridge, Massachusetts